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HVCN1 is the only mammalian voltage-gated proton channel. In
human B lymphocytes, HVCN1 associates with the B Cell Receptor
(BCR) and is required for optimal BCR signaling and redox control.
HVCN1 is expressed in malignant B cells that rely on BCR signaling,
such as Chronic Lymphocytic Leukemia (CLL) cells. However, little
is known about its regulation in these cells. We found that HVCN1
was expressed in B cells as two protein isoforms. The shorter
isoform (HVCN1S) was enriched in B cells from a cohort of 76 CLL
patients. When overexpressed in a B-cell lymphoma line, HVCN1S
responded more profoundly to PKC-dependent phosphorylation.
This more potent enhanced gating response was mediated by
increased phosphorylation of the same residue responsible for
enhanced gating in HVCN1L, Thr29. Furthermore, the association of
HVCN1S with the BCRwas weaker, which resulted in its diminished
internalization upon BCR stimulation. Finally, HVCN1S conferred a
proliferative and migratory advantage, as well as enhanced BCR-
dependent signaling. Overall, our data show for the first time the
existence of a shorter isoform of HVCN1 with enhanced gating
that is specifically enriched in malignant B cells. The properties
of HVCN1S suggest it may contribute to the pathogenesis of BCR
dependent B-cell malignancies.
proton currents j chronic lymphocytic leukemia j Hv1 j gating kinetics
j phosphorylation
Introduction
The voltage-gated proton channelHVCN1 (orHV1 orVSOP) is a
small protein that conducts protons across membranes selectively
(1, 2) and in a regulated manner. Previously, we described its
function in B lymphocytes, where proton channels sustain B Cell
Receptor (BCR) signaling via regulation of ROS production by
the NADPH oxidase enzyme complex (3). In addition, we found
HVCN1 to be directly associated with the BCR. Upon receptor
stimulation, the BCR and HVCN1 were co-internalized to late
endosomal/lysosomal organelles called MIICs, or MHC class II
containing compartments, where antigens bound to the BCR
are digested into small peptides and loaded onto MHC class II
molecules for presentation to T cells (3).
HVCN1 is expressed not only by normal but also bymalignant
B cells, such as Chronic Lymphocytic Leukemia (CLL). CLL cells
are characterized by their reliance on BCR signaling for survival
and growth (4), so it is possible that they maintain or upregulate
HVCN1 expression in order to sustain their growth. Other tumor
types have been found to rely on HVCN1 for survival, such as
breast (5) and colorectal cancer (6). In these tumor cells, proton
channels prevent excessive acidification of the cytoplasm and
allow increased cell migration. In malignant B cells, HVCN1
may regulate intracellular pH and at the same time sustain BCR
signaling. However, its precise roles remain to be elucidated.
We showhere that CLL cells and other B-cell lines specifically
express higher levels of a shorter isoform of HVCN1, HVCN1S.
We identified the existence of two distinct isoforms of relatively
similar size when immunoblotting B cell lysates with an HVCN1-
specific antibody (3). HVCN1S is only weakly expressed in normal
B cells and in light of its apparent upregulation in tumor cells,
we set out to characterize its function. We show that HVCN1S
responds more strongly to phosphorylation by PKC and identify
the phosphorylation site. We provide evidence that HVCN1S in
B cells is preferentially expressed at the plasma membrane, even
upon BCR stimulation and subsequent internalization, due to a
weaker association with the BCR. Lastly, we show that HVCN1S
expression results in stronger BCR signaling, increased prolifer-
ation and augmented chemokine-dependent migration. Overall,
our data indicate that HVCN1S is an alternative protein isoform
that mediates stronger currents upon PKC phosphorylation, is
more highly expressed at the plasma membrane, and can confer
a growth advantage to malignant B cells.
Significance
B lymphocytes are crucial cells in immune responses. Their
activity is regulated by signaling pathways involving reactive
oxygen species (ROS). Voltage-gated proton channels modu-
late B-cell responses by facilitating production of ROS. Here
we compare the full-length proton channel, HVCN1L, with a
shorter isoform, HVCN1S, which lacks the first 20 amino acids.
Cells with HVCN1S display greater proton channel activity
upon stimulation. In addition, HVCN1S is internalized to a
lesser extent by interactions with the B Cell Receptor, result-
ing in greater plasma membrane expression. Compared with
normal B lymphocytes, HVCN1S is expressed at higher levels in
B cells from patients with Chronic Lymphocytic Leukemia and
in B-cell lines, where its greater activity may contribute to the
pathogenesis of disease.
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Submission PDFFig. 1. HVCN1S is an alternative isoform of the voltage-gated proton channelHVCN1 enriched in malignant B cells.A) Left and center panels, immunoblots
showing expression of two isoforms of HVCN1, HVCN1L (‘L’) and HVCN1S (‘S’),
in B-cell lines, primary B cells and CLL samples. R=RI1, U=U2932 and H=HBL1
are Diffuse Large B Cell Lymphoma cell lines, E=EJM=multiple myeloma cell
line, Ra=RAJI=Burkitt lymphoma cell line. Right panel, densitometry analysis
of protein expression of HVCN1S in B cells from healthy donors (n = 7) and
CLL patients (n = 76). Protein expression levels as determined by western
blot, relative to loading control (β-actin or α-tubulin) and normalized to
a positive control used across different blots (cell line HBL1). Statistical
analysis carried out with Mann-Whitney U test. B) Left and center panels, in
vitro transcription-translation assays with recombinant HVCN1L andmutated
ttgHVCN1L. Right panel, expression of ttgHVCN1L transduced in LK35.2 cells.
C) PCR on HBL1 mRNA to identify the three mRNA sequences reported for
human HVCN1 (see Fig. S1). Left panel, duplex PCR with primers designed for
mRNA variant 2, which amplifies a band of 432 bps, and primers recognizing
all variants (228 bps). Right panel, PCR performed with different annealing
temperatures with primers designed to recognize HVCN1 mRNA variants 1
and 3. The expected bands for isoforms 1 and 3 are 433 and 393 bps, indicated
by arrows. D) Immunoblots of a CLL sample and LK35.2 cells overexpressing
HVCN1L and HVCN1S with an anti-HVCN1 that recognizes residues 26-46 (left
panel) and residues 1-20 (HVCN1L-specific, right panel).
Results
Identification of an HVCN1 isoform enriched in malignant B
cells. We investigated HVCN1 expression in a panel of B-cell
lines and noticed the presence of two bands of similar molecular
weight. Some cell lines appeared to express more of the shorter
isoform, while the Burkitt cell line Raji expressed it exclusively
(Fig. 1A, left panel). Peripheral blood B cells expressed this short
isoform (here called HVCN1S) at much lower levels compared to
CLL cells (Fig. 1A, center and right panel).
When we started this study, the NCBI DNA and RNA
database reported only one viable splicing variant for human
HVCN1 (See SI Appendix Fig. S1, variant 1). Given the presence
of an ATG 60 base pairs (bps) downstream of the first ATG,
we set out to investigate if a shorter isoform could be the result
of translation from this alternative start site. To this end, we
expressed recombinant HVCN1 Long (HVCN1L) in an in vitro
translation assay (Fig. 1B, left panel). We then mutated the first
ATG to TTG, which results in significantly reduced translation
from this codon (Fig. 1B, center panel). A shorter protein was
expressed from the mutated plasmid (Fig. 1B, center panel), also
when expressed in whole cells (Fig. 1C, right panel), indicating
that the second ATG functioned as a start codon.
More recently, three splicing variants for human HVCN1
have been reported (Fig. S1). Variant 1 and 2 differ in the use
of alternative 5′-UTRs but code for the same full-length HVCN1
protein, whereas variant 3 utilizes the same 5′-UTR as variant 1
but it does not possess the first coding exon. Therefore, variant
3 lacks the first ATG and consequently translation can start only
from the second ATG 60 bps downstream. To test the existence
of the three mRNA variants, we designed specific PCR primers
and tested them with mRNA from the cell line HBL1. We used
the same reverse primer and specific forward primers for variants
1/3 and 2, annealing on their respective 5′-UTRs. To distinguish
variants 1 and 3, we relied on differences in the band size of the
amplified PCR product (433 for variant 1 and 393 for variant 3).
As Fig. 1C left panel shows, the PCR with primers for variant 2
and all variants produced bands of the expected sizes. For variants
1 and 3, we ran a gradient PCR (Fig. 1C, right panel), which
showed the expected bands of 433 and 393 bps (Fig. 1C, arrows).
Overall, our results indicate the existence of three distinct mRNA
variants and therefore suggest that HVCN1S is the result of
alternative mRNA splicing, which produces a protein identical to
the long isoform but lacking the first 20 amino acids.
In order to confirm the nature of this shorter isoform, we
raised an antibody towards the first 20 amino acids of HVCN1,
which should recognize the long isoform only. Our original anti-
HVCN1 antibody, which recognizes a region in the N-terminus
closer to the first transmembrane domain (amino acids 26–46),
detected both isoforms in CLL cells (Fig. 1D left panel). Also,
recombinant HVCN1L and HVCN1S were both detected. In
contrast, an immunoblot with the anti-HVCN1L-specific antibody
only detected the long isoform, both recombinant and endoge-
nously expressed (Fig. 1D, right panel). These results confirmed
that the shorter isoform of HVCN1 is a protein with a shorter
N-terminus domain, lacking the first 20 amino acids.
Both isoforms are voltage-gated proton channels. Biophysical
properties of HVCN1L and HVCN1S were compared in trans-
duced LK-35.2 cells using the whole-cell voltage-clamp config-
uration over a wide range of pH. The H+ currents generated
by the two isoforms appeared generally similar. Fig. S2A (SI
Appendix) confirms that both isoforms were proton selective,
because the reversal potential for current (V rev) was close to the
Nernst potential for H+ (EH). This result is expected because the
selectivity filter is in the middle of the S1 transmembrane helix
(1), far from the N-terminus where the two isoforms differ.
A unique property of all known voltage-gated proton chan-
nels crucial to their function is △pH-dependent gating (2, 7). The
position of the proton conductance-voltage (gH-V ) relationship
depends strongly on both pHo and pHi, with the consequence that
the channel opens only when there is an outward electrochemical
gradient, and the open channel will extrude H+ from the cell.
HVCN1L and HVCN1S exhibited similar △pH-dependent gating,
both activating at potentials about 10 mV positive to V rev at
symmetrical pH (SI Appendix Fig. S2B).
To compare gating kinetics we used the perforated-patch
voltage-clamp method, a more physiological configuration that
preserves cytoplasmic contents. Comparison of the gating kinetics
of HVCN1L and HVCN1S in unstimulated LK-35.2 cells (SI
Appendix Table S1) reveals that HVCN1S channels opened more
slowly, with a time constant of current turn-on, τact, more than
double that of HVCN1L. Closing kinetics (τtail) and the position
of the gH-V relationship did not differ significantly.
HVCN1S responds more strongly to PKC-dependent phos-
phorylation. Proton currents in phagocytes and other cells are
greatly augmented by phosphorylation of the channel by protein
kinase C, PKC (8). The enhanced gating response is stimulated
effectively by the PKC activator, PMA, and is best studied using
the perforated-patch configuration that preserves intracellular
signaling pathways (9). Fig. 2 illustrates families of proton cur-
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Fig. 2. HVCN1S responds more strongly to PMA stim-
ulation than HVCN1L. Perforated-patch voltage clamp
was used to evaluate the electrophysiological proper-
ties of the two HVCN1 isoforms. Families of currents
in 10 mV increments up to 70 mV from Vhold = ‑40 mV
are shown in representative LK35.2 cells expressing
HVCN1L (A) or HVCN1S (B) before stimulation, after
application of the PKC activator PMA, and after in-
hibition of PKC by GF 109203X (GFX). Between the
families are superimposed currents obtained during
test pulses to 60 mV (for HVCN1L) or 40 mV (for
HVCN1S) applied at 30-s intervals before and after
addition of PMA or GFX to the bath solution. C) & D)
Proton conductance-voltage relationships, gH-V . The
current amplitude was determined by extrapolating
a single exponential fitted to the rising current, and
gH was calculated from the current using V rev mea-
sured in each solution. Measurements were made in
symmetrical pH 7.0 solutions containing 50 mM NH4+
to clamp pHi (9).
Fig. 3. HVCN1S is phosphorylated more by PKC-δthan HVCN1L. PKC-δ in
vitro kinase assay showing phosphorylation of HVCN1L and HVCN1S wild
type (‘WT’), single mutants T29A (‘29’) or T9A for HVCN1S (‘9’), S97A (‘97’)
or S77A for HVCN1S (‘77’), and double mutants T29A/S97A and T9A/S77A
for HVCN1S (‘DM’). The assay was carried out with recombinant HVCN1L
and HVCN1S expressed in HEK293T cells and immunoprecipitated with an
anti-myc antibody. Cells transfected with an empty vector (‘EV’) were used
as negative control. The myc immunoblot indicates loading. Bars represent
the densitometry analysis of the 32P-HVCN1 versus myc-HVCN1 of three
independent experiments (mean ± SEM). NS, not significant.
rents in cells expressing HVCN1L and HVCN1S, before and after
PMA stimulation. In response to PMA, the currents turn onmore
rapidly and at more negative voltages, turn off more slowly, and
the current amplitude is increased. Although HVCN1L responds
distinctly, the response of HVCN1S was consistently more pro-
found. Because there is a tendency early in each experiment for
proton currents to become larger and activate at more negative
voltages as the amphotericin in the pipette solution improves
electrical access to the cell membrane, and as pHi is clamped
to 7.0 by the applied NH4+ gradient (9, 10), the PMA response
may be exaggerated if measurements are made before complete
equilibration. A crucial quantitative control is to reverse the
effects of PMAusing the PKC inhibitor, GF 109203X (GFX). The
reversal of enhanced gating by GFX in both representative cells
in Fig. 2 was complete, validating the responses.
Fig. S3 (SI Appendix) shows normalized gH-V relationships
after the PMA response and after GFX treatment in all cells
studied expressing HVCN1L or HVCN1S. This comparison is
more informative than control vs. PMA for reasons just discussed
and because some cells were spontaneously active, as judged by
GFX reversal being greater than their initial response to PMA.
A possible spurious explanation for the greater PMA responsive-
ness of HVCN1S is that HVCN1L might have a greater tendency
to activate spontaneously. Fig. S3 does not support this view,
verifying that HVCN1S is indeed more responsive.
Fig. S4 (SI Appendix) summarizes the magnitude of the
changes in four kinetic parameters of HVCN1 gating result-
ing from PMA and GFX treatment of cells expressing the two
isoforms. For each parameter, the PMA response was signifi-
cantly greater in HVCN1S than HVCN1L. Also for each param-
eter, GFX reversed the PMA response completely. In summary,
HVCN1S channels exhibit amore profound response to phospho-
rylation than do HVCN1L channels.
Because B cells from CLL patients have higher than normal
levels of HVCN1S, their responsiveness might be enhanced. B
cells from CLL patients and normal controls were studied by
perforated-patch voltage clamp (n = 4 and 3, respectively), con-
firming that both CLL and normal B cells had proton currents
that responded to PMA andGFX. Interestingly, CLL cells, which
have a variable mixture of HVCN1S and HVCN1L (SI Appendix
Table S3) exhibited enhanced gating responses comparable with
those of LK35.2 cells expressing HVCN1S exclusively (SI Ap-
pendix Fig. S5), indicating that HVCN1S prevails in the response.
Identification of HVCN1S phosphorylation site. Two pre-
dicted high-probability PKC-δ phosphorylation sites exist in the
N-terminus of HVCN1L (11), Thr29 and Ser97. We reported pre-
viously that both sites were phosphorylated after PMA exposure,
but only Thr29 contributed detectably to the enhanced gating
response of HVCN1L channels (11). Because the lack of the
first 20 amino acids of the N-terminus might result in different
protein folding or architecture, it was important to examine the
contribution of both corresponding sites in HVCN1S, namely
Thr9 and Ser77. We generated mutants that lacked one (T9A and
S77A) or both (T9A/S77A) putative phosphorylation sites.
Cells with the T9A mutation (n = 9) and the double mutant
T9A/S77A (n = 5) did not respond detectably to either PMA
or GFX (SI Appendix Fig. S6), implicating Thr9 as crucial to
the responses. In contrast, cells expressing the S77A mutant did
respond to PMA and to GFX.Mean changes in parameter values
are given in SI Appendix Table S2. Therefore, the key residue in
the PMA response is Thr9 (HVCN1S), the equivalent of Thr29 in
HVCN1L channels (11). Any participation of Ser77 (HVCN1S) or
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Fig. 4. HVCN1S is associated and internalized with the BCR to a lesser
extent compared to HVCN1L. A) Left panel, confocal images of A20 D1.3
cells overexpressing HVCN1L or HVCN1S, at steady state (‘resting’ panels)
or 30 min after activation with an anti-IgM crosslinking F(ab')2 fragment
(‘activated’ panels). Merge panels represent IgM and HVCN1 staining. White
arrows indicate co-internalized HVCN1 and IgM. Right panels, quantification
of percentage of internalized HVCN1 (upper graph) and co-localization
coefficient for HVCN1 and IgM (lower graph). Each symbol represents a
single cell [n = 78 (upper); n = 67 (lower)], and horizontal lines indicate
the mean. Pearson's co-localization coefficient (0 = no co-localization, 1 =
total co-localization). B) Co-immunoprecipitation of overexpressed HVCN1L
or HVCN1S and endogenous CD79B (immunoglobulin-associated-β or Ig-β).
Proteins were co-immunoprecipitated from A20 D1.3 cells and analyzed by
immunoblot in non-reducing conditions. EV, cells transducedwith empty vec-
tor; IN, input cell lysate (2% of the cell lysate used for immunoprecipitation);
Ig, negative control beads conjugated to mouse or rat IgG; IP, immunopre-
cipitation; IB, immunoblot. Graphs represent densitometry analysis of both
co-IP experiments (mean ± SEM, three independent experiments).
Ser97 (HVCN1L) in the enhanced gating response was below our
ability to detect it.
Intriguingly, T9A cells studied before stimulation exhibited
9-fold faster activation and a 24-mV more negative V threshold than
did unstimulated HVCN1S cells (SI Appendix Table S1), resem-
bling enhanced gating mode behavior. We re-analyzed data from
analogous mutations studied previously in the full-length channel
(11) and found that T29A also exhibited “enhanced gating” in
unstimulated cells (Table S1). Unstimulated “phosphomimetic”
T29D cells exhibited weaker enhanced gating than T29A. Evi-
dently, this Thr position is a potent determinant of gating kinetics.
Together, these results suggest that phosphorylation of Thr29 in
HVCN1L or Thr9 in HVCN1S produces enhanced gating by a
mechanism not simply involving the negative charge provided by
the phosphate group. However, we cannot rule out the possibility
that these mutations alter gating through a mechanism unrelated
to that elicited by phosphorylation.
Since HVCN1S responded more strongly to PKC phosphory-
lation and the effect was mediated by phosphorylation of Thr9
exclusively, we speculated that it could reflect increased phos-
phorylation of this residue. Indeed, our in vitro kinase assay
Fig. 5. HVCN1S expression modulates BCR signaling, cell proliferation and
migration. A) BCR stimulation with 20μg/ml F(ab')2 anti-IgM in A20 D1.3
cells overexpressing empty vector (EV), HVCN1L and HVCN1S.Immunoblot
showing phosphorylated Erk (p-Erk) and total Erk. Bars indicate the ratio of
the densitometry analysis of p-Erk versus total Erk from three independent
experiments (mean + SEM). B) Proliferation of A20 D1.3 cells assessed by
EdU incorporation after 3 h incubation. Results are shown as percentage of
Edu+ cells versus total number of GFP+ cells of two independent experiments
(mean + SEM). C) Transwell chamber migration assay towards the chemokine
CXCL12. Migrated cells were counted after 4 h. Results are shown as fold
increase of the percentage of migrated cells in the presence of CXCL12 versus
media alone. Data represent the average of two experiments (mean + SEM).
showed that overall phosphorylation of wild-type HVCN1S was
significantly higher than for wild-type HVCN1L (Fig. 3, WT lanes
in left panel). In order to assess phosphorylation of the critical
PKC site mediating the enhanced-gating response, we carried
out the same experiment with T29A (T9A for HVCN1S), S97A
(S77A for HVCN1S), and T29A/S97A (T9A/S77A for HVCN1S)
mutants. As shown in Fig. 3, phosphorylation of the T9A mutant
was reduced as much as for the T29A one, confirming that this
Thr is phosphorylated by PKC in both isoforms. The analysis of
the other PKC sitemutant, S97A (S77A forHVCN1S) and double
mutants indicated a further reduction in overall phosphorylation,
as we reported previously for HVCN1L (11), suggesting that
the Ser is also phosphorylated by PKC. However, as before, the
patch-clamp experiments (SI Appendix Fig. S6 and Table S1)
indicated that phosphorylation of Thr9 alone is responsible for
the enhancement of HVCN1S proton currents.
HVCN1S has a weaker association with the BCR than does
HVCN1L. We found previously that HVCN1 was associated with
the BCR in both normal and malignant B cells (3). The associ-
ation causes HVCN1 to be internalized together with the BCR
after its stimulation, an event that downregulates HVCN1 expres-
sion at the cell surface (3). Since the intracellular domains are
likely to be the regions mediating the association with the BCR,
we investigated if HVCN1S behaved differently from HVCN1L.
We overexpressed both isoforms in the B lymphoma cell line
A20 D1.3 and assessed their expression at steady state and after
BCR stimulation with a F(ab′)2 anti-IgM. Cells expressed similar
levels of HVCN1, IgM, and the BCR co-receptor CD79B (SI
Appendix Fig. S7A-C). We did not notice significant differences
in the pattern of expression of the two isoforms at steady state. Im-
portantly, however, upon BCR stimulation, the extent of HVCN1
internalization for the two isoforms appeared different (Fig. 4A).
Quantification of the immunofluorescence staining showed a
significantly larger percentage of internalized HVCN1 in cells
expressing HVCN1L compared to HVCN1S (36% vs. 25%, Fig.
4A, upper graph). Furthermore, the extent of co-localization with
IgM was also reduced from 0.562 to 0.407 (Fig. 4A, lower graph).
DiminishedHVCN1S internalization was not due to reduced IgM
internalization, which was actually increased, compared to cells
overexpressing HVCN1L (SI Appendix Fig. S7D). These data
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indicate that HVCN1S association with the BCR is different and
this results in increased localization of proton channels at the
plasma membrane.
In order to determine the reason for the different associa-
tion of HVCN1 isoforms with the BCR, we carried out a co-
immunoprecipitation (co-IP) with an anti-CD79B and the recip-
rocal experiment with an anti-myc (for the myc-tagged HVCN1
isoforms). As shown in Fig. 4B, interaction of HVCN1S with
CD79B was indeed significantly weaker with both co-IP assays.
The differences between the two antibodies are likely due to
differences in the efficiency of pull down (with the anti-myc being
more efficient than the anti-CD79B). Overall, these data show
that the first 20 amino acids present in HVCN1L are critical for
the association with the BCR and their absence in HVCN1S re-
sults in greater expression of this isoform at the plasmamembrane
after BCR stimulation.
HVCN1S expression is enriched in CLL cells. Given the
increased expression HVCN1S in B-cell lines and in CLL samples
(Fig. 1A), combined with its ability to mediate stronger proton
currents (Fig. 2), we investigated whether its expression could
have an impact on CLL disease progression. To this end we
analyzed the expression of HVCN1S in a cohort of 76 samples of
peripheral blood CLL cells with annotated clinical data. Details
of the patients’ characteristics are reported in SI Appendix Table
S3. The samples investigated showed variable expression of both
isoforms, with an average ratio of HVCN1S to HVCN1L of 0.52 ±
0.034 (mean ± SE). As shown in Fig. 1A, HVCN1S was markedly
higher in CLL than in primary B cells from healthy donors, in
which HVCN1S is barely detectable. Given the wide range of
HVCN1S expression in CLL cells, we split samples in two groups,
one with a ratio of HVCN1S/HVCN1L below the median value
of 0.477 (i.e., with lower expression of HVCN1S), and one with
higher HVCN1S expression (above themedian). A Kaplan-Meier
curve for overall survival showed patients with higher expression
of HVCN1S had reduced overall survival, although differences
did not reach statistical significance (SI Appendix Fig. S8). We
further analyzed the data specifically for the two main subgroups
of CLL patients, those presenting a mutated variable region in
the BCR heavy chain (IGHV ) and those with an unmutated
IGHV . Given the small number of samples for which we knew the
mutation status (SI Appendix Fig. S8 and Table S3), it was not
surprising that differences did not reach statistical significance,
nonetheless higher expression of HVCN1S tended to correlate
with a poorer outcome in both groups.
HVCN1S expression results in stronger BCR-dependent sig-
naling, proliferation and chemokine-dependent migration. In
order to establish if HVCN1S could confer a growth advantage
to malignant B cells, we first assessed BCR-dependent signaling
in A20 D1.3 cells transduced with empty vector (EV), HVCN1L
and HVCN1S. As shown in Fig. 5A, the presence of HVCN1S
resulted in more prolonged activation of the extracellular signal-
regulated kinase (Erk), which is responsible for the upregulation
of several anti-apoptotic proteins in CLL cells (12). Furthermore,
to determine if the two proton channel isoforms regulated cell
proliferation, we measured the extent of EdU incorporation, a
nucleoside analogue included into nascent DNA. Interestingly,
only HVCN1S provided a significant advantage compared to EV
cells (Fig. 5B).
Another important property of CLL cells is the ability to
respond to the chemokine CXCL12, which affects their migra-
tion, homing and survival (13). Since HVCN1 was shown to
regulate migration of breast cancer (5) and colorectal cells (6), we
set out to characterize if HVCN1 isoforms affected chemokine-
dependent migration in a B-cell setting. As Fig. 5C shows, both
HVCN1L and HVCN1S expression resulted in increased migra-
tion to CXCL12, however, only HVCN1S resulted in a significant
advantage. Taken together, these data indicate thatHVCN1S pro-
motes malignant B-cell survival through enhanced proliferation
and migration.
Discussion
Only one proton channel gene has been identified in any species.
However, the human gene can generate two different isoforms,
HVCN1L and HVCN1S (3). In this paper, we confirmed the
existence of alternative splicing variants as reported in the NCBI
nucleotide database, presenting evidence that translation of
HVCN1S starts at an alternative ATG. The resulting protein is
20 amino acids shorter at the N-terminus, as confirmed here by
immunoblotting with an antibody raised against the first 20 amino
acids of full-length HVCN1 (HVCN1L). Compared to peripheral
B cells from healthy donors, B-cell lines and CLL cells showed
increased expression of total HVCN1 due to an upregulation of
HVCN1S. Higher levels of HVCN1S tended to correlate with
decreased overall survival in a cohort of 76 blood samples from
CLL patients. Given the wide range of expression of HVCN1S in
CLL and the limited number of samples analyzed, it would be
necessary to screen a much larger panel of samples in order to
determine if this trend is significant. This would be particularly
interesting for the mutated CLL subgroup, since these patients
have a more favorable prognosis overall, however, some still
present more aggressive disease and markers to identify this
subpopulation are lacking.
Comparison of their electrophysiological properties revealed
that HVCN1S channels open about twice slower than HVCN1L.
A more profound difference was seen in response to stimula-
tion by PMA. Agonists that activate PKC strongly amplify the
proton conductance in many human and mammalian cells (8,
9, 14-18), a phenomenon called “enhanced gating.” Although
both isoforms responded to PMA, the HVCN1S response was
significantly greater. This differential responsiveness enables cells
to modulate proton channel activity by preferential expression
of HVCN1S or HVCN1L isoforms. That the PMA response of
CLL cells resembled that of LK35.2 cells expressing exclusively
HVCN1S reveals that in a mixture of isoforms, HVCN1S will
dominate due to its lower V threshold.
The distinct gating of the two isoforms HVCN1S and
HVCN1L that differ only in the first 20 amino acids of the N-
terminus emphasizes the importance of this intracellular domain
in modulating gating kinetics. Proton channels are thought to
open as a result of outward movement of the S4 transmem-
brane helix (19-21). Being an extension of the S4 helix, the C
terminus affects gating directly (22). Nevertheless, gating kinetics
is modulated drastically (a) in the enhanced gating mode by
phosphorylation of Thr29 (11), (b) by the point mutation T9A in
HVCN1S or T29A in HVCN1L (SI Appendix Table S1), and (c)
in the naturally occurring mutation M91T (23), all of which are
localized to the N-terminus.
Because T9A and T9A/S77A mutants failed to respond to
PMAorGFX, enhanced gating ofHVCN1S is evidently mediated
entirely by phosphorylation of Thr9. This residue is equivalent to
Thr29, the key phosphorylation site producing enhanced gating in
HVCN1L (11). Here we show that phosphorylation of Thr9 and
overall phosphorylation is greater in HVCN1S than in HVCN1L,
suggesting that the loss of the first 20 amino acids facilitates phos-
phorylation of this residue. Additionally, the mechanism by which
phosphothreonine orchestrates enhanced gatingmay bemodified
in HVCN1S. Whether the two isoforms are phosphorylated at
steady state in tumor B cells will depend upon expression and
activation of PKC in these cells. Because PKC was expressed and
activated in the great majority of CLL samples investigated (SI
Appendix Table S3), we believe constitutive phosphorylation of
proton channels in CLL cells to be highly likely.
Furthermore, we present evidence that HVCN1S has a
weaker association with the BCR, which results in greater ex-
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pression at the plasma membrane and reduced internalization
upon BCR stimulation. Evidently, the first 20 amino acids of
HVCN1 are important for association with the BCR. It will be
interesting to investigate which residues in HVCN1 are involved
in this interaction and whether there is a direct association with
the BCR complex (either the immunoglobulin or the co-receptors
CD79A and CD79B) or if additional scaffolding proteins are
involved. Malignant B cells such as CLL cells are stimulated
through their BCR in the tumor microenvironment and each
round of stimulation normally results in BCR internalization (4).
That tumor B cells upregulate an isoform ofHVCN1 that remains
at the plasma membrane more after BCR stimulation suggests
these cells might find plasma membrane expression of HVCN1S
beneficial to their growth. This is corroborated by the advantage
in BCR-dependent Erk activation, proliferation, and chemokine-
dependent migration conferred by HVCN1S. Higher levels of
HVCN1 expression correlate with metastatic tendency and poor
prognosis in breast cancer (5) and colorectal cancer (6); although
the isoform involved has not been reported.
Overall, our data show the existence of a shorter isoform
of HVCN1 with enhanced gating responses that is specifically
enriched in malignant B cells. The enhanced gating of HVCN1S
produces larger proton currents in CLL cells that may contribute
to the pathology, as suggested by stronger BCR signaling, in-
creased cell proliferation and chemokine response provided by
HVCN1S expression
Materials and Methods
Cell lines and plasmids. The mouse B lymphoma cell lines LK35.2 HyHEL10
(IgG2a, κ-chain; H-2kxd) and A20 D1.3 (IgG2a, κ-chain; H-2d) overexpressing
recombinant IgM receptors were a gift from F. Batista. The cells were
transduced with MigRI retroviral vectors coding for myc-tagged HVCN1L or
HVCN1S. T29A (T9A for HVCN1S), S97A (S77A for HVCN1S), and T29A/S97A
(T9A/S77A for HVCN1S) mutants were generated using QuikChange site-
directedmutagenesis kit (Stratagene). The retroviral particles were produced
in Phoenix α packaging cell line as described elsewhere (11).
Phosphorylation assay. HEK293T cells were transfected by Ca2+ phos-
phate with myc-tagged HVCN1L, HVCN1S, and mutant plasmids. 48 h after
transfection, cells were lysed in 20 mM Hepes, 1% Triton X-100, 137 mM
NaCl, 2.5 mM β-glycerophosphate, 1 mMNa3VO4, 2 mM EDTA, and proteases
inhibitors (Sigma Aldrich). 1 mg of proteins was immunoprecipitated with
anti-myc tag antibody (9B11, Cell Signaling Technology) conjugated to
protein-G Sepharose beads for 1 h. After washing with lysis buffer, beads
were incubated in 40 μl kinase assay buffer (20 mM Hepes, 1 mM EGTA, 0.4
mM EDTA, 5 mM MgCl2, 0.1 mM CaCl2, 0.05 mM dithiothreitol, 0.1 mg/ml
phosphatidyserine, 0.01 mg/ml diacylglycerol, 2.5 mM β-glycerophosphate, 1
μMPMA, 100 nM PKC-δ (Millipore), 100 μM cold ATP and 10 μCi of [γ-32P]ATP
(Perkin Elmer) for 20 min at 30°C. The reaction was stopped by resuspending
beads in 2× Laemmli sample buffer. Samples were then separated by SDS-
PAGE, transferred to a nitrocellulose membrane and exposed to X-ray films.
Membranes were immunoblotted with anti-myc antibody to determine
loading.
Electrophysiology. Whole-cell or perforated-patch variants of the
patch-clamp techniquewere carried out as described in detail previously (24).
Perforated-patch studies included225 μM amphotericin B in the pipette to
permeabilize the patchmembrane, and 50mMNH4+ to clamp pHi to pHo. For
whole-cell studies, the main pipette solution (also used externally) contained
(in mM) 130 TMACH3SO3, 2 MgCl2, 2 EGTA, 80 Mes, titrated to pH 5.5 with
20 TMAOH. Bath solutions at pH 7.0 had (in mM) 90 TMACH3SO3, 3 CaCl2,
1 EGTA, 100 BES, and 36-40 TMAOH. When pH was varied, buffers with pKa
near the desired pH were used: Homopipes for pH 4.6, MES for pH 5.5-6.0,
BisTris for pH 6.5, HEPES for pH 7.5, and Tricine for pH 8.0. Experiments were
done at 21ºC or at room temperature (20-25°C). No leak correction has been
applied to current records.
Patch-clamp Studies of CLL and healthy B cells. Cells were shipped
frozen on dry ice. After thawing, they were suspended in RPMI with serum,
centrifuged at 1100 rpm for 5 min and resuspended in a small volume (1-2
ml) of RPMI with serum.
Statistics. Statistical analysis was carried out by Student’s unpaired t-test.
Further materials and methods are provided in Supporting Information
Appendix.
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